A quant. anal. method for pharmacokinetics and bioavailability of breviscapine phospholipid complex self-microemulsions in Beagle dogs was established.Beagle dogs were administered with breviscapine phospholipid complex self-microemulsions and breviscapine tablets at single dose, resp.HPLC was adopted to determine the concentration of scutellarin in plasma with mobile phase of methanol-0.2% phosphoric acid solution (45:55) and detection wavelength at 335 nm.Pharmacokinetics parameters and bioavailability were calculated by DAS2.1.1 software program.Plasma concentration-time profiles of scutellarin in these two preparations were fitted to double-compartment model, Tmax of breviscapine phospholipid complex self-microemulsions and breviscapine tablets were 190 min and 160 min, Cmax were 78.98 mg·L-1 and 33.63 mg·L-1, and AUC0-t were 18674.619 mg·L-1·min and 9132.475 mg·L-1·min, resp.Relative bioavailability of self-microemulsions relative to tablets was 204.49%.Breviscapine phospholipid complex self-microemulsions can significantly improve bioavailability of scutellarin in Beagle dogs, which provides a new direction for development of oral preparations of breviscapine.